Close  

Managing COVID-19 by increasing testing capacities

/ 05:00 PM July 16, 2020

JENKA Global, a company which brings and showcases innovative and global-quality products, offers in vitro diagnostic rapid test to the Philippine market in a bid to detect the presence of immunoglobulin (Ig)M and IgG antibodies to coronavirus disease 2019 (COVID-19) in a patient’s blood specimen.

The Food and Drug Administration-approved rapid test kit includes a combo test card, sample buffer, capillary pipet, and instructions for use.

ADVERTISEMENT

Medical professionals, who follow the standard laboratory procedure and biosafety guidelines for handling and disposal of potentially infectious material, have to keep the kit to room temperature before testing, withdraw the blood specimen with the capillary pipet provided, add two drops of sample buffer to well, and then read the result at 15 minutes. 

Boson rapid test meets the EN-ISO 13485 standards and has sensitivity of 87.8 percent, specificity of 99 percent, and accuracy of 96.8 percent. 

FEATURED STORIES

Manufactured by Xiamen Boson Biotech Co. Ltd. — a specialist in the in-vitro diagnostic kits field, developing and manufacturing high-quality point-of-care and other immunoassay kits for the worldwide market — it delivers the result in 15 minutes.

Mr. Liu Bin, Quality Manager of Xiamen Boson Biotech Co. Ltd., reminds the public that “Based on clinical data, our products have high accuracy. However, according to the general detection guidelines for COVID-19, a definitive clinical diagnosis should not be based on the result of nucleic acid or antibody tests alone, and should be made after all clinical and laboratory findings have been evaluated, including nucleic acid tests, antibody tests, and clinical symptoms.”

He further adds, “All manufacturers inevitably encounter incidences of false positives and negatives. We can only ensure that each batch of products achieves the optimal quality through our strict control of raw materials, optimization of technical details, and strict quality control throughout our R&D and production processes.”

“This COVID-19 pandemic has shaken the entire world and we need to be vigilant to keep our family, our community and ourselves safe,” shares Ms. Koko Tamura, Marketing Manager of Jenka Global, OPC. “We believe that the best way to manage this is to know, and when more people can get tested, the better we have a chance to manage existing cases and prevent further spread.”

Tamura also reiterates the importance of choosing the right type of brand. “Boson has been in this business for more than two decades and present in over 70 countries. They have superior R&D and extensive quality control measures which are important factors when choosing the right rapid test kit.”

ADVERTISEMENT

ADVT

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
EDITORS' PICK
MOST READ
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, rapid test kits, Xiamen Boson Biotech Co. Ltd.
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.